DEA Adds Second Step to Reporting Procedure for Controlled Substance Theft or Loss - Reed Smith LLP
DEA now requires a second reporting step for controlled substance theft or loss: in addition to filing Form 106 with the DEA, pharmacies must also report to the local DEA field division office within one business day of discovery.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmacies handling controlled substances (independent, retail chain, compounding, long-term-care) should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; the change is effective upon publication.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
DEA added a requirement to notify the local DEA field division office within one business day of discovering a theft or significant loss, in addition to the existing Form 106 filing.
Who it affects
All pharmacies handling controlled substances (independent, retail chain, compounding, long-term-care)
What you must do
Update your theft/loss reporting procedures to include immediate notification to the local DEA field office.
Deadline
Immediately; the change is effective upon publication.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- Murphy signs bill scheduling tianeptine as Schedule II controlled substance in New Jersey - WRNJ Radio
- TX HB 7: Relating to prohibitions on the manufacture and provision of abortion-inducing drugs, including the jurisdiction of and effect of certain judgments by courts within and outside this state with respect to the manufacture and provision of those drugs, and to protections from certain counteractions under the laws of other states and jurisdictions; authorizing qui tam actions.
- US-CONGRESS HR7895: PBM Kickback Prohibition Act
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661